Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Immunol Allergy Clin North Am. 2020 Aug;40(3):461–470. doi: 10.1016/j.iac.2020.04.004

Figure 2.

Figure 2.

Clinical presentation of IKAROS-associated primary immunodeficiency by mechanism of action. Percentage indicates penetrance of clinical disease in IKAROS mutation carriers.